Cagrilintide Research Guide

Full name: Cagrilintide (AM833)

A long-acting amylin analog being investigated for obesity, both on its own and in a fixed-ratio combination with semaglutide (CagriSema). Amylin is a hormone co-secreted with insulin that promotes satiety and slows gastric emptying.

How Cagrilintide Works

Acts as a dual amylin and calcitonin receptor agonist. It engages satiety centers in the area postrema and hindbrain, reducing food intake and slowing gastric emptying through a pathway distinct from GLP-1.

Dosing Protocol

• Typical dose: 0.3-2.4 mg (titrated)
• Frequency: Once weekly
• Duration: Ongoing while needed
• Route: Subcutaneous injection

Reported Benefits

• Appetite suppression and increased satiety
• Meaningful weight loss
• Complements GLP-1 agonists (additive effect)
• Slows gastric emptying

Potential Side Effects

• Nausea (dose-dependent)
• Reduced appetite
• Injection site reactions
• Constipation or GI upset

Research Citations

1. Cagrilintide once weekly for weight management (2021) - Phase 2 trial showed dose-dependent weight loss up to ~10.8% at 26 weeks vs ~3% placebo.
2. CagriSema (cagrilintide + semaglutide) in obesity (2023) - Combination achieved roughly 15-17% weight loss, exceeding either agent alone.

Related Weight Management Compounds

• AOD-9604 - Full Profile
• Semaglutide - Full Profile
• Tirzepatide - Full Profile
• Retatrutide - Full Profile
• Tesofensine - Full Profile
• CagriSema - Full Profile

View full Cagrilintide profile with 3D molecule viewer →